Innate Pharma S.A. (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma S.A. (OTCMKTS:IPHYF - Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 4,200 shares, a growth of 100.0% from the March 31st total of 2,100 shares. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 3.2 days. Approximately 0.0% of the company's stock are short sold.

Innate Pharma Price Performance

OTCMKTS:IPHYF remained flat at $1.45 on Friday. Innate Pharma has a 1 year low of $1.45 and a 1 year high of $1.76. The firm has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.36.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.